LENZ Therapeutics, Inc. LENZ
3.92
0.20
5.38%
as of 25 Sep
- Market cap
- $117.4M
- P/E
- 0.0×
Follow LENZ
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(28.78%) | (33.63%) | (49.71%) | (59.21%) | |
| (27.09%) | (31.52%) | (46.01%) | (55.52%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(30.68%) | (29.18%) | (44.73%) | (58.05%) | |
Average Days of Receivables |
— | 0.00 | 5.96 | 7.51 | |
Free Cash Flow per Share |
(1.62) | (2.43) | (2.79) | (3.65) | |
Free Cash Flow |
(46.16) | (70.00) | (87.44) | (114.42) | |
Capital Expenditures |
(0.94) | (0.83) | (0.73) | (0.51) | |
Piotroski F-Score |
2.00 | 2.00 | 4.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(11.42%) | (11.99%) | (17.17%) | (25.93%) | |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.85 | 0.90 | |
Inventory Turnover |
— | — | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 644.02 | 570.41 | |
Days of Inventory on Hand |
0.00 | 0.00 | 206.13 | 353.59 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | — | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 595.48% | 705.78% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 68.18% | 74.22% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.77 | 0.84 | 0.80 | 0.90 | |
Depreciation/Fixed assets |
0.16 | 0.24 | 0.33 | 0.45 | |
Capex/Depreciation |
(4.58) | (2.88) | (2.03) | (1.13) | |
Revenue per Share |
0.00 | 0.00 | 0.67 | 0.68 | |
Operating CF per Share |
(1.58) | (2.40) | (2.77) | (3.63) | |
Capex per Share |
(0.03) | (0.03) | (0.02) | (0.02) | |
Capex to Sales |
0.00 | 0.00 | 0.04 | 0.02 | |
Net Profit Margin |
0.00% | 0.00% | (519.30%) | (586.74%) |
Columns are period end dates